RedHill Biopharma Announces Positive End-of-Phase II Meeting with FDA on BEKINDA® for IBS-D The positive Type B meeting with the FDA followed a successful Phase II study of BEKINDA® for diarrhea-predominant irritable bowel syndrome (IBS-D), one of the most common gastrointestinal disorders ...